All Oncology News

Adding cabazitaxel to ADT and radiotherapy did not improve PFS or MFS vs SOC after 7 years among patients with high-risk localized prostate cancer.

Disitamab vedotin elicited response rates over 50% in previously treated HER2-expressing advanced urothelial carcinoma.

Perioperative enfortumab vedotin plus pembrolizumab improved EFS and OS in cisplatin-eligible muscle-invasive bladder cancer.

Lutetium Lu 177 vipivotide tetraxetan–based therapy generated similar QOL outcomes compared with ADT plus an ARPI alone in patients with mHSPC.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Roswell Park Comprehensive Cancer Center's Adult Multidisciplinary Neurofibromatosis Clinic was added to the NF Clinic Network.

The alpha-emitting radionuclide actinium-225 was well tolerated and produced PSA responses across all dose levels in patients with mCRPC.

Survey results highlight the top RCC and bladder cancer abstracts to watch at the 2026 Genitourinary Cancers Symposium.

In IMvigor011, adjuvant atezolizumab drove ctDNA clearance and improved DFS in ctDNA-positive muscle-invasive bladder cancer.

Long-term follow-up data from PEACE-3 showed enzalutamide plus radium-223 improved OS and rPFS in patients with mCRPC and bone metastases.

Short-course darolutamide boosted PSMA expression in some high-risk localized prostate cancer, supporting improved PSMA PET imaging strategies.

The addition of capivasertib to abiraterone elicited an rPFS advantage and preserved QOL compared with placebo plus abiraterone in PTEN-deficient mHSPC.

Gurbakhash Kaur, MD, discusses the exploration of CELMoDs in multiple myeloma care and how they may affect the treatment paradigm.

Abiraterone acetate, prednisone, and olaparib combination therapy boosted efficacy outcomes in first-line mCRPC.

The FDA expanded the indication for zongertinib in unresectble or metastatic nonsquamous NSCLC harboring HER2 TKD mutations.

The bispecific ADC iza-bren elicited PFS and OS benefits compared with chemotherapy in pretreated, unresectable, locally advanced or metastatic TNBC.

Keck Medicine of USC researchers found a potential way to break the blood-brain barrier to improve immune checkpoint inhibitor efficacy in recurrent, high-grade astrocytoma.

Obrixtamig plus platinum chemo showed a 72% response rate and manageable safety in frontline DLL3-positive NEC in the phase 1 DAREON-7 trial.

Richard D. Kim, MD, discusses how positive results from PODIUM-303 exemplify and support the shift towards chemoimmunotherapy regimens in frontline SCAC.

A large transcriptomic analysis identified actionable gene fusions in 9% of glioblastomas, defining a targetable molecular subset.

Mario Sznol, MD, discusses adjuvant vs neoadjuvant immunotherapy in melanoma and highlights emerging vaccines, cell therapies, and T-cell engagers.

Encorafenib plus cetuximab and fluorouracil-based chemotherapy has received traditional FDA approval for BRAF V600E–mutant metastatic colorectal cancer.

Mayo Clinic has installed the first magnetic nanoparticle-mediated hyperthermia machine for cancer research in the US.

R. Lor Randall, MD, FACS, discusses a report on factors predicting local recurrence in nonmetastatic Ewing sarcoma from the phase 3 AEWS1031 trial.

Ashkan Emadi, MD, PhD, discusses how subcutaneous blinatumomab may represent a treatment approach in mixed phenotype acute leukemia.

Novel pembrolizumab-based combination regimens showed similar efficacy to the reference regimen in first-line ccRCC.

An analysis showed the manufacturing and distribution of Orca-T was consistent for patients with hematologic malignancies.

Real-world data show liso-cel drives high responses in relapsed/refractory CLL, with an 85% ORR, a 44% CR rate, and manageable safety.

Huntsman Cancer Institute will soon become the first academic medical center in the US to manufacture a new prostate cancer imaging drug.

Sophia O’Brien, MD, discusses the role of nuclear medicine in lobular breast cancer diagnosis and staging, as well as use criteria for FES-PET/CT.